Evaluation of the role of her2 oncogene as a benchmark for the prognosis of breast cancer

One of the most important diagnostic factors in breast cancer, which is one of the most common causes of death in women, is HER2 oncogene. One of the most important determinants in the prognosis is the segmentation of the tumor stages. Among these, tumor size, the status of the acne lymph nodes in terms of the possibility of tumor returning accurate information can be given to us. Among these we can refer to the HER2 proto-oncogene as one Mention the most important biomarkers. According to the latest research, HER2 protoxogonectomy is known as a measure of prognosis in breast cancer. This proto-oncogene is a 581 kDa glycoprotein receptor in the membrane, which has intracellular activity of tyrosine kinase. The incidence of HER2 from the epidemiological point of view in breast cancer is 18-20%, which is a significant figure. Already, in relation to the importance of HER2 oncogene as a diagnostic agent, there are different opinions, including the theory of incidence HER2 in the untreated primary tumor tissue as a prognostic factor. It is important to perform the HER2 test to help diagnose and validate the anti HER2 treatment process as well as an important factor in determining its role in prognosis. HER2 factor is considered as a diagnostic factor between the incidence of return on Breast cancer and its direct relationship with excessive HER2 incidence have a meaningful relationship that can not confirm the return of all cancer tumor markers

Keywords:

Breast Cancer , Cancer Prevention , Cell and Cancer , Cancer Risks , Cancer Genetics